Application of Pregabalin in the Treatment of Neuropathic Pain

Neuropathic pain is pain caused by a lesion or disease of the somatosensory system. Treatment for neuropathic pain is usually aimed at reducing the severity of symptoms, as the cause of the pain is rarely treatable. An important role in the therapy of neuropathic pain belongs to pregabalin, presented on the Ukrainian pharmaceutical market under the trade name Linefor by the company «Polpharma», the largest Polish drug manufacturer, represented on the markets of more than 60 countries and is the leader in the number of patent applications in the European Patent Office for 2022. Pregabalin has been approved by the U.S. Food and Drug Administration for the treatment of neuropathic pain associated with diabetic peripheral neuropathy, spinal cord injury, postherpetic neuralgia, and fibromyalgia. It is also used as adjunctive therapy for partial seizures in adults with epilepsy. The effectiveness of pregabalin has been confirmed in a series of clinical trials, which reported a reduction in pain intensity and improvement in sleep quality in patients with neuropathic pain, indicating the reliability and feasibility of its use in the therapy of patients with various forms of neuropathic pain, providing a significant symptoms relief and improving patients’ quality of life.